PCPhilip Man Chiu Choi

Philip Man Chiu Choi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philip Man Chiu Choi has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tenecteplase Efficacy in Patients With Distal Occlusions: Secondary Analysis of the TASTE Randomized Clinical Trial

    by Vignan Yogendrakumar, Justin Phung, Hannah T. Johns, Leonid Churilov, Carlos Garcia-Esperon, Gagan Sharma, Niruta Dhimal, Chushuang Chen, Longting Lin, Beng Lim Chew, et al.

    BACKGROUND: Tenecteplase has been previously evaluated in large- and medium-sized vessel occlusion subgroups, but its effectiveness in more distal occlusions, particularly those involving the distal middle cerebral artery branches or the anterior cerebral artery and posterior cerebral artery territories, and across varying ischemic core and perfusion profiles, remains uncertain. METHODS: We performed a secondary analysis of TASTE (Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation), a randomized clinical trial comparing tenecteplase and alteplase in patients presenting within 4.5 hours of symptom onset with perfusion imaging-confirmed stroke and evidence of target mismatch (penumbra/core ratio >1.8 and an absolute difference >15 mL). The primary outcome was the modified Rankin Scale (mRS) score of 0 to 1 at 90 days. We compared the effect of tenecteplase versus alteplase in subgroups based on occlusion site (proximal M2, distal M2, M3 and beyond, anterior cerebral artery, and posterior cerebral artery), ischemic core, core growth rate, and penumbra. The treatment effect of tenecteplase and alteplase was compared stratifying by the subgroup of interest, adjusting for age, baseline National Institutes of Health Stroke Scale score, and premorbid mRS score in modified Poisson regression models. RESULTS: Of the 680 patients enrolled, 492 were included in the primary analysis (median age, 73 [interquartile range, 63–82] years; male sex: 306/492 [62%]). Two hundred forty-two (49%) received tenecteplase, and 250 (51%) received alteplase. Tenecteplase was associated with a higher proportion of mRS score of 0 to 1 with distal (M3 and beyond) occlusions (tenecteplase: 62/81 [77%] versus alteplase: 59/93 [63%]; adjusted risk ratio, 1.23 [95% CI, 1.04–1.46]). Numerically higher rates of mRS score of 0 to 1 were observed with distal M2 (tenecteplase: 30/46 [65%] versus alteplase 28/48 [58%]; adjusted risk ratio, 1.14 [95% CI, 0.84–1.54]) and anterior cerebral artery occlusions (tenecteplase: 12/21 [57%] versus alteplase 5/13 [38%]; adjusted risk ratio, 1.46 [95% CI, 0.71–3.00]). No treatment differences were seen for proximal M2 or posterior cerebral artery occlusions ( P interaction across all occlusion sites: 0.89). Across ischemic core, penumbra, and core growth rate subgroups, no difference in treatment effect was observed. CONCLUSIONS: Patients with distal middle cerebral artery occlusions who are treated with tenecteplase are more likely to achieve an mRS score of 0 to 1 at 90 days than those treated with alteplase. REGISTRATION: URL: https://www.anzctr.org.au ; Unique identifier: ACTRN12613000243718.

  • Open Access

    Application of the STAT model for demand management to reduce specialist clinic waiting times: protocol for the WaitLESS stepped wedge cluster randomised controlled trial

    by Katherine E Harding, Patrick Carney, Annie K Lewis, Julie Considine, Natasha Brusco, Luke Prendergast, David Snowdon, Mitchell N Sarkies, Philip Choi, Em Bould, et al.

    Introduction: Patients frequently face excessive waiting times for specialist medical outpatient clinics, negatively impacting health outcomes. Previous research has demonstrated that translation of demand-driven strategies incorporated within the evidence-based Specific Timely Assessment and Triage (STAT) model effectively reduces wait times in a range of healthcare settings. We outline the study protocol for a hybrid type II implementation effectiveness study, using a stepped wedge cluster randomised controlled trial design, to evaluate whether the STAT model can be implemented in specialist medical clinics and reduce waiting times. Methods: The Waiting List Evidence to Support Specialist clinics (WaitLESS) trial will implement STAT in eight clinical specialties (clusters) offering outpatient medical care at a metropolitan health network in Melbourne, Australia. After a 6 month pre-implementation period, clusters will be randomised to implement the STAT model, two clusters at a time at 3-month intervals, with a minimum 6-month follow-up period, following the STAT model’s five-step implementation process: (i) analyse historical clinic demand data, (ii) model supply/demand, (iii) implement target interventions to address existing backlogs, (iv) protect capacity for new patients to align with demand and (v) implement tailored strategies to enhance patient flow. Strategies will be implemented collaboratively by researchers and clinical teams. The trial will measure both effectiveness (reductions in waiting time and patients on the waiting list) and implementation (fidelity, adoption, acceptability, feasibility, appropriateness and cost) outcomes, using quantitative healthcare data and qualitative data from staff and patients. Analysis: Linear mixed-effects models will be used for analysis of the primary effectiveness outcome of waiting time from referral to first appointment, with time point and time since intervention as factor variables. Implementation outcomes will be analysed descriptively, with qualitative data mapped deductively to the Consolidated Framework for Implementation Research. A cost of implementation and cost-effectiveness analysis will be completed from the health service perspective. Trial registration number: ISRCTN15820171 .

  • Association of Successful Recanalization and Functional Outcomes in Minor Ischemic Stroke With Proven Occlusion: A Secondary Analysis of TEMPO-2 Trial

    by Nishita Singh, Daniel Strbian, Shabnam Vatanpour, Thalia S. Field, Amy Y.X. Yu, Aravind Ganesh, Philip A. Barber, Philip M.C. Choi, Brian H. Buck, Timothy J. Kleinig, et al.

    BACKGROUND: Complete recanalization of cerebral arteries is strongly associated with good functional outcome in ischemic stroke. We hypothesize that successful recanalization results in better functional outcomes. METHODS: This is a secondary observational cohort analysis of TEMPO-2 (Tenecteplase Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion), a randomized controlled trial comparing tenecteplase with standard of care (control) in minor stroke (National Institutes of Health Stroke Scale score ≤5) with intracranial occlusion/focal perfusion abnormality ≤12 hours of onset. Among those enrolled based on computed tomography angiography with visible occlusion, a follow-up computed tomography angiography was done at 4 to 8 hours after randomization. The primary outcome was return to baseline functional outcomes using the modified Rankin Scale score at 90 days. Safety outcomes included stroke progression (National Institutes of Health Stroke Scale score ≥2 worsening), bleeding events, and mortality. Patients with successful recanalization, defined as revised Arterial Occlusive Lesion score ≥2b/3, were compared with those with unsuccessful recanalization on follow-up computed tomography angiography. Regression analysis was used to assess the association of successful recanalization with outcomes after adjusting for age, sex, baseline stroke severity, and onset-to-randomization time. RESULTS: Of the 886 enrolled patients, 517 (58.3%) with follow-up computed tomography angiography were included. Of these, 178 (34.6%) had successful recanalization (122 [68.5%]: tenecteplase, 56 (31.5%): control), and 336 (65.4%) did not achieve successful recanalization (unsuccessful recanalization; 134: tenecteplase, 202: control). Baseline characteristics were similar between patients with and without successful recanalization. Successful recanalization was significantly associated with the primary outcome as compared with unsuccessful recanalization (adjusted risk ratio, 1.21 [95% CI, 1.07–1.34]). Patients with successful recanalization had significantly lower rates of stroke progression as compared with unsuccessful recanalization (2.8% versus 13.1%, adjusted risk ratio, 0.21 [95% CI, 0.08–0.52]). Multivariable analysis showed that tenecteplase treatment was the strongest independent predictor of successful recanalization (odds ratio, 3.48 [95% CI, 2.33–5.18]). CONCLUSIONS: Successful recanalization is a critical determinant of early and 90-day functional recovery in patients with minor stroke with intracranial occlusion, regardless of treatment modality. Tenecteplase significantly increases the odds of achieving successful recanalization compared with standard care. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02398656.


  • Intracranial Hemorrhage Patterns and Outcomes in Minor Stroke: Analysis of the TEMPO-2 Trial

    by Sara Massicotte, Shabnam Vatanpour, Cody Doolan, Jianhai Zhang, Aravind Ganesh, Philip M.C. Choi, Brian H. Buck, Thalia S. Field, Amy Y.X. Yu, Timothy J. Kleinig, et al.

    BACKGROUND: Intracranial hemorrhage (ICH) negatively impacts functional outcomes after ischemic stroke, with potentially disproportionate impacts in patients with minor stroke. This study aimed to evaluate the effect of ICH on outcomes in minor ischemic stroke and to identify predictors associated with ICH. METHODS: This was a secondary analysis of the TEMPO-2 (A Randomized Controlled Trial of Tenecteplase Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion) multicenter, randomized trial, which compared tenecteplase with nonthrombolytic standard care in patients within 12 hours of symptom onset with minor stroke (National Institutes of Health Stroke Scale score ≤5) and a visible vessel occlusion or perfusion mismatch. Follow-up imaging was assessed for hemorrhage using the Heidelberg classification. Symptomatic ICH was defined as any hemorrhage associated with neurological deterioration. The primary outcome was return to premorbid functional status at 90 days, measured using the modified Rankin Scale. Mixed-effects regression was used to assess the effect of ICH status on outcomes, adjusting for treatment, age, sex, baseline stroke severity, and onset-to-randomization time, with region included as a random effect. RESULTS: Among 884 participants, 865 had complete 24-hour imaging and follow-up. Using complete case analysis (n=865), any ICH occurred in 102 participants (11.8%). Patients with any ICH (median age, 70 years; 35.3% females) more frequently had premorbid hypertension (71.6% versus 57.7%) and atrial fibrillation (28.4% versus 18.1%). Any ICH was not associated with reduced odds of returning to baseline neurological function (adjusted odds ratio, 0.93 [95% CI, 0.87–1.00]) but was associated with higher 90-day mortality (9.8% versus 1.8%; adjusted hazard ratio, 3.71 [95% CI, 1.54–8.95]). Rates of any ICH were higher in tenecteplase than standard care (14.4% versus 9.2%; P =0.02), although most were petechial hemorrhagic transformations. Symptomatic ICH rates, although numerically higher, were not significantly different between the tenecteplase versus control arms (8 [1.9%] versus 2 [0.5%]; P =0.06). CONCLUSIONS: Although most hemorrhages were minor, the presence of any ICH was strongly associated with increased mortality, highlighting that even minor hemorrhagic transformation may be prognostically significant in patients with minor ischemic stroke.

  • Outcomes After Minor Ischemic Stroke in Older Patients Treated With IV Thrombolysis vs Standard of Care in the TEMPO-2 Trial

    by Aravind Ganesh, Shabnam Vatanpour, Amy Ying Xin Yu, Philip Barber, Philip Man Chiu Choi, Thalia S. Field, Mahesh P. Kate, Timothy John Kleinig, Michel Christopher Frank Shamy, Kausik Chatterjee, et al.

    There are few high-quality data on thrombolysis outcomes in the oldest patients, especially for minor stroke. We examined safety and efficacy outcomes of thrombolysis in patients older than 80 years, compared with those ≤80 years, in the Tenecteplase Versus Standard of care for Minor Ischaemic Stroke With Proven Occlusion (TEMPO-2) trial. In this post hoc analysis of the TEMPO-2 randomized controlled trial, we compared outcomes and adverse events in patients with minor stroke and symptomatic intracranial occlusion or focal perfusion lesion within 12 hours of symptom onset, assigned to tenecteplase vs nonthrombolytic standard of care, in those >80 years and ≤80 years. The primary outcome was responder analysis of the 90-day modified Rankin Scale (responder was mRS = 0-1 if premorbid mRS = 0-1, 0-2 if premorbid mRS = 2). Secondary outcomes included neurologic recovery according to the NIH Stroke Scale (NIHSS) at 5 days/discharge, vessel recanalization, Lawton Instrumental Activities of Daily Living Scale, EuroQol-5 Dimension (EQ-5D), and adverse events. We used mixed-effects Poisson, ordinal logistic, and quantile regression as appropriate, adjusted for sex, baseline NIHSS, and treatment assignment as fixed-effects and enrolling site as random effects. Among 884 patients in the intention-to-treat analysis (208 [23.5%] >80 years, 365 [41.6%] female). Significant interactions between age and treatment were observed for mRS responder, mRS 0-1, return to baseline function, EQ-5D index, and vessel recanalization. Patients >80 years generally fared worse with tenecteplase for mRS outcomes (mRS 0-1 in 49 [46.2%] vs 61 [59.8%] with control, adjusted risk ratio [aRR] 0.83, 95% CI 0.72-0.97), while among patients ≤80 years, there was no significant difference (249 [76.4%] vs 260 [74.7%], aRR 1.01, 95% CI 0.98-1.03). However, in both age groups, patients were more likely to achieve recanalization of visible occlusions (aRR ≤80 years 2.06, 95% CI 1.60-2.65, >80 years 2.77, 95% CI 2.21-3.47) and NIHSS = 0 at 5 days/discharge when assigned to tenecteplase (aRR ≤80 years 1.14, 95% CI 1.04-1.26, >80 years 1.21, 95% CI 1.10-1.33). Serious adverse events (SAEs) were more frequent with tenecteplase among patients >80 years (risk ratio 2.29, 95% CI 1.27-4.13), particularly hemorrhages and stroke progression/recurrence (any extra/intracranial hemorrhage in 5 [4.7%] vs 0 with standard of care, p = 0.026). Older patients (>80 years) with minor stroke and visible occlusion or perfusion lesion assigned to tenecteplase were more likely to achieve recanalization of occlusions and short-term neurologic recovery, as were younger patients, but they experienced worse 90-day outcomes with more frequent hemorrhagic and stroke progression/recurrence-related SAEs. Overall, these results, while post hoc, do not support thrombolysis for minor strokes in older patients. ClinicalTrials.gov: NCT02398656. This study provides Class III evidence that in patients >80 years with minor stroke and visible occlusion or perfusion lesion, IV thrombolysis with tenecteplase is associated with worse functional outcomes at 90 days compared with nonthrombolytic standard of care therapies.


  • Testing for Primary Aldosteronism Underutilized Following Stroke: A Multicenter Cohort Study

    by Josephine McCarthy, Jocelyn Widjaja, Frank M. Gao, Ignatius J.H. Lee, Jordan H.N.C. Lai, Muhammad Akram, Sanjana Gupta, Philip M.C. Choi, Thanh G. Phan, Jun Yang

    BACKGROUND: Primary aldosteronism, the most common endocrine cause of hypertension, is associated with an increased risk of stroke compared with essential hypertension. Targeted treatment with mineralocorticoid receptor antagonists, or surgical resection of an aldosterone-producing adrenal adenoma, can effectively reduce blood pressure and mitigate cardiovascular risk. However, despite being a highly modifiable cardiovascular risk factor, primary aldosteronism is grossly underdiagnosed, even in high-risk populations. METHODS: We conducted a multicenter retrospective cohort study to assess the frequency of primary aldosteronism testing among patients admitted between January 2019 to January 2020 with stroke or transient ischemic attack. Data, including blood pressure, antihypertensive medication use, serum potassium, and adrenal imaging, were collected from the medical records of patients admitted for stroke or transient ischemic attack at 2 large tertiary hospitals in Victoria, Australia. RESULTS: Among 400 patients (mean age, 73.9±13.4 years; 42.1% female), 30% (n=120) had a clinical indication for primary aldosteronism testing, yet only 2% (n=8) were tested. CONCLUSIONS: These findings highlight a missed opportunity to identify a treatable cause of hypertension in patients at high risk of recurrent cerebrovascular events. Routine testing for primary aldosteronism in stroke care pathways may improve long-term outcomes through targeted intervention.


  • Efficacy of Tenecteplase in Large Vessel Occlusion Stroke Within 24 Hours of Symptom Onset: The ETERNAL-LVO Randomized Controlled Trial

    by Vignan Yogendrakumar, Bruce C V Campbell, Leonid Churilov, Carlos Garcia-Esperon, Philip M C Choi, Dennis J Cordato, Niruta Dhimal, Liudmyla Olenko, Prodipta Guha, Gagan Sharma, et al.

    BACKGROUND: To assess the efficacy and safety of tenecteplase in patients presenting within 24 hours of symptom onset with a large vessel occlusion and target mismatch on perfusion computed tomography. METHODS: ETERNAL-LVO (Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients With Large Vessel Occlusion) was a prospective, randomized, open-label, blinded end point, phase 3, superiority trial where adult participants with a large vessel occlusion, presenting within 24 hours of onset with salvageable tissue on computed tomography perfusion, were randomized to tenecteplase 0.25 mg/kg or standard care across 11 primary and comprehensive stroke centers in Australia. The primary outcome was the modified Rankin Scale score of 0 to 1 or return to baseline at 90 days via a modified Poisson regression model. Secondary outcomes include the modified Rankin Scale, considered as an ordinal variable, and symptomatic intracerebral hemorrhage. RESULTS: Following trial initiation, a supply shortage of the investigational product hindered recruitment. When supply resumed, phase 3 evidence had emerged supporting tenecteplase use within 4.5 hours of stroke onset, including large vessel occlusion. ETERNAL-LVO was, therefore, terminated early. Two hundred forty-two participants (median age: 73 years, 43% female, 79% undergoing EVT) were included in the modified intention-to-treat analysis; 120 received tenecteplase and 122 received standard care. No difference in the primary outcome was observed between the tenecteplase (n=44, 37%) and standard care (n=52, 43%; adjusted risk ratio, 0.90 [95% CI, 0.66–1.21]; P =0.48). No significant differences in an ordinal analysis of the modified Rankin Scale were observed between the 2 treatment groups. In a planned per-protocol analysis, the odds of improvement by 1 point in the modified Rankin Scale were doubled in the tenecteplase-treated transfer subgroup compared with standard care transfer patients (odds ratio, 2.61 [95% CI, 1.07–6.40]). Symptomatic intracerebral hemorrhage occurred in 5 (4%) participants assigned to tenecteplase and was present in 1 (1%) participant assigned to standard care. CONCLUSIONS: Treatment with tenecteplase did not increase the likelihood of a favorable functional outcome, but early stoppage of the study prevents definitive conclusions from being drawn. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04454788.


  • Cost-Effectiveness of Endovascular Thrombectomy in Large Vessel Occlusion Stroke for the Very Elderly

    by Peter Lee, Teddy Wu, Chushuang Chen, Longting Lin, Carlos Garcia-Esperon, Dennis John Cordato, Ferdinand Miteff, Timothy John Kleinig, Philip Man Chiu Choi, Cheng Xin, et al.

    Endovascular thrombectomy (EVT) is associated with considerable clinical benefits for patients after large vessel occlusion (LVO) stroke. However, EVT remains underused in Australia, particularly among the very elderly (aged ≥80 years). The aim of this study was to evaluate the cost-effectiveness and clinical effectiveness of EVT vs standard medical management among very elderly patients using real-world, observational data. A modeled cost-effectiveness study was conducted from the Australian health care perspective. Data from a retrospective cohort of patients aged 80 years or older treated with EVT at 4 comprehensive stroke centers across Australia and New Zealand, as well as data from the International Stroke Perfusion Imaging Registry, were used to inform our economic analyses. The distribution of 90-day modified Rankin Scale (mRS) outcomes after propensity score matching was used to inform a decision-analytic Markov model. Costs and utility data for calculating quality-adjusted life years (QALYs) were drawn from published sources. The primary outcome of this analysis was the incremental cost-effectiveness ratio (ICER) in terms of cost per QALY gained for EVT compared with medical management. Uncertainty was evaluated with deterministic and probabilistic sensitivity analyses. A total of 548 patients (mean age 85.1 years and 296 women [54%]) were included to inform the propensity score matching analysis. After propensity score matching, the proportion of patients with favorable (mRS score ≤2) outcomes was higher for EVT vs standard care (37% vs 18%). Based on the modeled cost-effectiveness analysis comprising a hypothetical sample of 10,000 patients, EVT was estimated to prevent 471 deaths over a period of 15 years. On a per-patient basis, EVT was associated with a gain of 0.95 years of life and 0.97 QALYs at a net cost of AU$3,399. That is, from a health care perspective, EVT is cost-effective for very elderly patients with LVO stroke (ICER: $3,508 per QALY). Sensitivity analyses supported the robustness of the model, with 100% of simulated ICERs falling below the commonly accepted Australian willingness-to-pay threshold of AU$50,000 per QALY. EVT is cost-effective and associated with considerable clinical benefits relative to standard medical management for very elderly patients with LVO stroke. Our findings support the provision of EVT to the very elderly.


  • Open Access

    Reducing hospital length of stay with criteria-led transfer from the acute stroke unit to inpatient rehabilitation

    by Peishan Cai, Karen Stephens, Jane D’souza, Louisa Soh, Emily Schembri, Philip MC Choi

    Background: Criteria-led transfer allows transfer of select stroke patients to inpatient rehabilitation without rehabilitation physician review, which may be a barrier for timely transfers. Objective: Primary: determine the proportion of patients transferred via criteria-led transfer and waitlist time. Secondary: determine the number of unplanned 30-day acute hospital representations and readmissions from inpatient rehabilitation, and number of daily allied health contacts while waitlisted. Method: A single-centre retrospective analysis was conducted on all patients transferred from the acute stroke unit to inpatient rehabilitation in 2023. Results: 178 (79%) patients successfully used criteria-led transfer, 22 (9.5%) did not meet criteria and the remainder attended inpatient rehabilitation via a separate pathway. Median waitlist time (in days) was shorter for criteria led transfer patients compared with those who did not meet criteria (3 (1–5) vs 5 (3–8), p=0.005). Emergency department representation rates were lower in the criteria-led transfer cohort (30 (16.9%) vs 8 (36.3%), p=0.03) compared with those who did not meet criteria. No difference in readmission rates was seen (p=0.22). Waitlisted patients received 1 (0.5–1.5) allied health reviews daily. Conclusions: Criteria-led transfer is associated with shorter waitlist times for transfer to rehabilitation without increased adverse events. Further research is needed to determine result generalisability.


  • Open Access

    Bridging the Urban and Regional Divide in Stroke Care (BUILDS): A Novel Telestroke Unit Service

    by Lauren Arthurson, Suzanne Harrison, Benjamin Clissold, Christopher Bladin, Glenn Howlett, Felix Ng, Philip M. C. Choi

    Problem: People living in rural areas of Australia have an increased risk of stroke. Reperfusion decision support is increasingly available in these areas however, access to acute stroke unit care is limited.Setting: An acute telestroke unit pilot was implemented in a regional health service in Victoria.Key Measures for Improvement: Change in diagnosis post specialist evaluation, patient and staff satisfaction, length of stay, percentage of patients discharged with anti‐platelets and care plan provision.Strategies for Change: Partnership between metro‐based stroke specialists and an onsite stroke coordinator based in a regional site. Early engagement of key decision makers (i.e., hospital executive).Effects of Changes: This model increased diagnostic accuracy and decreased resource use including diagnostic tests, patient transfers and staff deployment. Patients, families and staff reported high levels of satisfaction. The pilot transitioned to a sustainable health service funded model, embedded into ‘usual’ care. The BUILDS pilot enabled stroke unit certification of the regional health service.Lessons Learnt: Telestroke unit model, enabled by an adequately resourced local stroke coordinator, could be the key to ensure all regional Australians have access to stroke unit care.